Abdulkadir Yılmaz

Dr. Abdulkadir Yılmaz

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2026 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
EGEnis Burak Gül
Enis Burak Gül
ÜKÜmit Kervan
Ümit Kervan
SKSinan Sabit Kocabeyoğlu
Sinan Sabit Kocabeyoğlu
AYAbdulkadir Yılmaz
Abdulkadir Yılmaz
MAMUSTAFA AKDİ
MUSTAFA AKDİ
HZHatice Zengin
Hatice Zengin
Objective: Left ventricular assist devices (LVADs) are a essential therapy option for children with end-stage heart failure, aiming to prolong survival and enhance quality of life during the wait for heart transplantation. This study evaluated the impact of aortic geometry and outflow graft angle on the development of aortic insufficiency (AI) following LVAD implantation in pediatric patients. Methods: This retrospective study included 22 pediatric patients under the age of 18 who underwent isolated LVAD implantation between 2014 and 2024. Aortic geometry, outflow graft angles, and aortic valve function were assessed using echocardiography and computed tomography. The development of postoperative AI was monitored over a 1-year period using a validated grading system from the literature. Patients were categorized into two groups based on AI severity; AI < 1 (none or trivial) and AI ⩾1 (mild or greater). Results: The mean age was 12.1 years and 77.3% of the patients were male. Median survival, as estimated by Kaplan–Meier analysis, was 1.555 days. At 12 months, 40.9% of patients had developed mild AI. A significant negative correlation was found between AI and aortic root diameter, sinotubular junction (STJ) diameter and proximal ascending aortic diameter. ROC analysis identified an aortic root diameter of ⩽22.1 mm as a threshold predictive of AI. Conclusion: Long-term LVAD support appears to be a safe and effective strategy in pediatric patients. The overall risk of AI was low and the effect of outflow graft angle on complications was limited. Aortic root diameter may serve as an important predictor of AI development. In this population, developing surgical technique and device positioning to individual anatomical characteristics may improve clinical outcomes.

31 December 2022 in Genel Tıp Dergisi
Verified
Journal Article
Open access
PDF file
MKMehmet Karahan
Mehmet Karahan
DSDoğan Emre SERT
Doğan Emre SERT
AYAbdulkadir Yılmaz
Abdulkadir Yılmaz
FYFatih Yamac
Fatih Yamac
STServet Turgut
Servet Turgut
ESErol Sener
Erol Sener
Background/Aims: In this study, the results of patients who had orthotopic heart transplantation (OHT) in acute rejection who admitted to our clinic with decompensated heart failure and who could not undergo endomyocardial biopsy (EMB) were evaluated. Methods: The study included 27 patients who underwent OHT in our clinic between December 1998 and November 2021, who admitted with acute rejection causing decompensated heart failure during follow-up, and who could not undergo EMB and administered IV pulse steroid plus plasmapheresis. Demographics of patients, peri-treatment left ventricular functions, survival rates and causes of mortality were analyzed. Results: 19 (70.4%) were male and mean age was 28.7 ± 14.7 (range: 3-54). After OHT, overall survival rates were 92.6%, 77.6%, and 69.4% at 1st, 3rd and 5th year respectively. During the follow-up, the survival rates of patients who presented with decompensated heart failure and given pulse steroid plus plasmapheresis were 70.4%, 58.8%, and 53.4% at 1st, 3rd and 5th year respectively after plasmapheresis. Median rejection time after transplant was 19 months (range 0-113 months). Pre-, and post-treatment left ventricle ejection fractions were 25.11% ± 11.1%, and 52.14% ± 13.4% respectively (p<0.05). The leading causes of mortality were pneumonia causing sepsis (5/13 patients). Conclusions: In acute rejection patients with decompensated heart failure in whom EMB is not possible, administration of plasmapheresis in addition to IV pulse steroid therapy may have a positive effect on survival in this patient group. Özet Amaç: Bu çalışmada ortotopik kalp nakli (OHT) yapılan, takip sırasında dekompanze kalp yetmezliğine neden olan akut rejeksiyon ile kliniğimize başvuran ve endomiyokardiyal biyopsi (EMB) yapılamayan hastaların sonuçları değerlendirildi. Yöntemler: Çalışmaya Aralık 1998-Kasım 2021 tarihleri arasında kliniğimizde OHT yapılıp, takip sırasında dekompanze kalp yetmezliğine neden olan akut rejeksiyon ile başvuran ve EMB uygulanamayan, IV pulse steroid + plazmaferez uygulanan 27 hasta dahil edildi. Hastaların demografik özellikleri, tedavi öncesi sol ventrikül fonksiyonları, sağkalım oranları ve mortalite nedenleri analiz edildi. Bulgular: Hastaların 19'u (%70.4) erkekti ve yaş ortalaması 28.7 ± 14.7 (3-54) idi. OHT sonrası genel sağkalım oranları 1., 3. ve 5. yılda sırasıyla %92.6, %77.6 ve %69.4 idi. İzlemde dekompanze kalp yetmezliği ile başvuran ve pulse steroid + plazmaferez uygulanan hastaların plazmaferez sonrası 1., 3. ve 5. yılda sağkalım oranları sırasıyla %70.4, %58.8 ve %53.4 idi. Nakil sonrası median rejeksiyon süresi 19 aydı (0-113 ay). Tedavi öncesi ve sonrası sol ventrikül ejeksiyon fraksiyonları sırasıyla %25.11±%11.1 ve %52.14±%13.4 idi (p<0.05). Mortalitenin önde gelen nedeni ise sepsise neden olan pnömoni (5/13 hasta) idi. Sonuç: EMB'nin yapılmasının mümkün olmadığı dekompanze kalp yetmezliği olan akut rejeksiyon hastalarında, IV pulse steroid tedavisine ek olarak plazmaferez uygulanması sağkalımı olumlu etkileyebilir.

Verified
Journal Article
Open access
PDF file
MAMUSTAFA AKDİ
MUSTAFA AKDİ
BABekir Boğaçhan Akkaya
Bekir Boğaçhan Akkaya
AYAbdulkadir Yılmaz
Abdulkadir Yılmaz
SKSinan Sabit Kocabeyoğlu
Sinan Sabit Kocabeyoğlu
ÜKÜmit Kervan
Ümit Kervan
As survival after left ventricular assist device (LVAD) implantation improves, an increasing number of patients require non-cardiac surgery (NCS) during follow-up. This study aimed to evaluate the clinical characteristics and perioperative management of LVAD recipients undergoing NCS and to compare outcomes between elective and emergent procedures. Among 434 adults who underwent LVAD implantation between 2014 and 2026, 42 subsequently underwent NCS and were classified into elective (n = 26) and emergent (n = 16) groups. Overall, 9.68% of LVAD recipients required NCS, of which 61.9% were elective. Preoperative urea, creatinine, and international normalized ratio (INR) levels were significantly higher in the emergent group. Thirty-day mortality (31.2% vs. 3.8%; p = 0.023) and 1-year mortality (68.8% vs. 30.8%; p = 0.026) were significantly higher after emergent surgery. Kaplan–Meier analysis demonstrated significantly lower survival in the emergent group (log-rank p = 0.018). On univariable Cox regression analysis, emergent surgery was associated with a 2.87-fold higher mortality risk (HR, 2.87; 95% CI, 1.15–7.15; p = 0.024). NCS after LVAD implantation can be performed safely with appropriate patient selection, anticoagulation management, and multidisciplinary care; however, emergent surgery is associated with a less favorable preoperative clinical profile, limited opportunity for anticoagulation optimization, and substantially higher mortality.

4 April 2026 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
AYAbdulkadir Yılmaz
Abdulkadir Yılmaz
DSDoğan Emre Sert
Doğan Emre Sert
ÜKÜmit Kervan
Ümit Kervan
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
EGEnis Burak Gül
Enis Burak Gül
EŞErol Şener
Erol Şener
Purpose: The conventional triple immunosuppressive regimen administered following heart transplantation typically comprises a calcineurin inhibitor, an antiproliferative agent, and corticosteroids. Everolimus has emerged as a viable alternative to calcineurin inhibitors. This study aims to evaluate the immunosuppressive efficacy and adverse effect profile of everolimus when introduced after the first post-transplant year, in comparison to continued calcineurin inhibitor therapy. Methods: A retrospective analysis was conducted on 90 heart transplant recipients under regular follow up. Patients were categorized into two groups: those who maintained calcineurin inhibitor therapy beyond the first year post-transplant ( n = 45), and those who transitioned to everolimus after the first year ( n = 45). The groups were compared in terms of rejection incidence and side effects. Results: Following the treatment modification, the everolimus group showed a significant improvement in serum urea and creatinine levels ( p < 0.05). Rejection rates after the first year were found to be similar between the two groups. Conclusion: Everolimus provides effective immunosuppression with a lower rate of side effects.It demonstrates a favorable impact on renal function without increasing the risk of rejection.The first year may be recommended as the optimal timing, considering both safe wound healing and the risk of rejection.

11 April 2026 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
MAMUSTAFA AKDİ
MUSTAFA AKDİ
AYAbdulkadir Yılmaz
Abdulkadir Yılmaz
SKSinan Sabit Kocabeyoğlu
Sinan Sabit Kocabeyoğlu
ÜKÜmit Kervan
Ümit Kervan
Background: Advanced heart failure in inherited arrhythmogenic cardiomyopathies poses significant therapeutic challenges, particularly in pediatric patients. Naxos syndrome represents a rare form of such cardiomyopathy, in which mechanical circulatory support may be required. Case description: We present a case of a 14-year-old girl with Naxos syndrome who developed refractory cardiac decompensation complicated by malignant ventricular arrhythmia, necessitating central veno-arterial extracorporeal membrane oxygenation (VA-ECMO) followed by implantation of a HeartMate III left ventricular assist device (LVAD). Conclusion: This report highlights the multidisciplinary management, surgical decision-making, and perioperative challenges encountered during treatment, emphasizing the role of central ECMO as an effective bridge to durable LVAD support and heart transplantation in young patients with complex cardiomyopathies.

19 August 2026 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
AYAbdulkadir Yılmaz
Abdulkadir Yılmaz
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
ÜKÜmit Kervan
Ümit Kervan
MKMehmet Karahan
Mehmet Karahan
BABekir Boğaçhan Akkaya
Bekir Boğaçhan Akkaya
ZÇZeki Çatav
Zeki Çatav
Objective: The pediatric patient group undergoing left ventricular assist device (LVAD) implantation is small and unique. Many efforts have been made to prolong survival. In our study, we aimed to evaluate the effects of levosimendan administration on postoperative outcomes in pediatric patients undergoing LVAD implantation. Methods: This retrospective single-center study included patients under 18 years of age who underwent LVAD implantation. Patients with INTERMACS class 1 were excluded from the study. Patients were divided into two groups: Group A ( n = 14), who received levosimendan preoperatively in addition to standard inotropic therapy, and Group B ( n = 17), who received standard inotropic therapy alone. Levosimendan was administered at a dose of 0.1 µg/kg/min for 72 h without a loading bolus. Primary outcomes were early right ventricular failure and in-hospital mortality. Secondary outcomes included the need for right ventricular assist, late right ventricular failure, and changes in organ function as assessed by liver and kidney function tests. Safety points for drug administration were defined as arrhythmia, hypotension, and sudden arrest. Results: Baseline characteristics (except LVEDD), ventricular function, and vasoactive inotropic scores were similar between the groups. No significant difference was observed in terms of early right ventricular failure, in-hospital mortality, or length of hospital stay. The rates of need for right ventricular assist and late right ventricular failure were comparable. Improvements in organ function were observed in both groups; significantly greater reductions in aspartate aminotransferase and alanine aminotransferase levels were recorded in the levosimendan group. No treatment-limiting side effects were observed. Conclusion: Preoperative levosimendan administration seems to be safe in pediatric LVAD candidates and is associated with improved end-organ function, although it has not demonstrated superiority over standard inotropic therapy in terms of preventing right ventricular failure or reducing mortality.